mds-2026-gba-lrrk2-genetic-susceptibility

MDS 2026 — GBA and LRRK2 Genetic Susceptibility in Parkinson's Disease

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

This page synthesizes research on GBA and LRRK2 genetic risk factors, gene-environment interactions, and their implications for Parkinson's disease pathogenesis and therapeutic targeting presented at MDS 2026.

Overview

[GBA](/genes/gba) (Glucocerebrosidase) and [LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) represent the two most significant genetic risk factors for Parkinson's disease (PD). Together, they account for a substantial proportion of both familial and sporadic PD cases. MDS 2026 highlighted recent advances in understanding how these genetic risk factors interact with environmental exposures to modify disease risk, phenotype, and progression.

1. GBA-Associated Parkinson's Disease

Genetic Architecture

[GBA](/genes/gba) variants are the most significant genetic risk factor for sporadic PD, with 5-10% of PD patients carrying pathogenic variants[@gba2024]. Unlike monogenic forms, GBA-associated PD demonstrates a complex inheritance pattern with variable penetrance.

MDS 2026 — GBA and LRRK2 Genetic Susceptibility in Parkinson's Disease

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

This page synthesizes research on GBA and LRRK2 genetic risk factors, gene-environment interactions, and their implications for Parkinson's disease pathogenesis and therapeutic targeting presented at MDS 2026.

Overview

[GBA](/genes/gba) (Glucocerebrosidase) and [LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) represent the two most significant genetic risk factors for Parkinson's disease (PD). Together, they account for a substantial proportion of both familial and sporadic PD cases. MDS 2026 highlighted recent advances in understanding how these genetic risk factors interact with environmental exposures to modify disease risk, phenotype, and progression.

1. GBA-Associated Parkinson's Disease

Genetic Architecture

[GBA](/genes/gba) variants are the most significant genetic risk factor for sporadic PD, with 5-10% of PD patients carrying pathogenic variants[@gba2024]. Unlike monogenic forms, GBA-associated PD demonstrates a complex inheritance pattern with variable penetrance.

| Mutation Category | Common Variants | Effect on GCase Activity | PD Risk |
|------------------|-----------------|--------------------------|---------|
| Severe | L444P, 84GG, IVS2+1G>A | <5% residual activity | 20-30x increased |
| Moderate | N370S, E326K | 15-40% residual activity | 5-10x increased |
| Risk-modifying | T369M, P387L | Mild reduction | 1.5-3x increased |

Genotype-Phenotype Correlations

The relationship between GBA genotype and clinical phenotype in PD follows a dose-response pattern based on residual GCase activity:

| Genotype | Age of Onset | Motor Severity | Cognitive Decline | Progression Rate |
|----------|--------------|----------------|-------------------|------------------|
| N370S heterozygous | 55-60 years | Moderate | Moderate | Intermediate |
| L444P heterozygous | 50-55 years | Severe | Early/frequent | Fast |
| 84GG heterozygous | 48-52 years | Severe | Very early | Very fast |
| Compound heterozygous | 45-50 years | Very severe | Very early | Very fast |

Carrier Frequency in PD Populations

GBA carrier frequency varies significantly across populations:

| Population | PD Carrier Frequency | General Population | Odds Ratio |
|------------|---------------------|-------------------|------------|
| Ashkenazi Jewish | 15-20% | 5-6% (N370S) | 5-10x |
| European descent | 5-10% | 1-2% | 5-7x |
| East Asian | 3-5% | <1% | 3-5x |
| African descent | 2-4% | <1% | 2-4x |

Key insight: The carrier frequency of severe GBA variants (L444P, 84GG) in PD patients is approximately 10x higher than in the general population, while risk-modifying variants show more modest enrichment.

Molecular Mechanisms

The connection between GBA dysfunction and PD involves multiple interconnected pathways:

Clinical Phenotype

GBA-PD represents a distinct clinical subtype with characteristic features:

• Earlier age at onset: Mean 5-10 years earlier than idiopathic PD
• Faster cognitive decline: Higher risk and earlier onset of PD dementia
• Earlier autonomic dysfunction: Orthostatic hypotension, gastrointestinal symptoms
• Distinct sleep architecture: RBD may precede motor symptoms
• Higher non-motor symptom burden: Anxiety, depression, anosmia

Therapeutic Implications

| Approach | Mechanism | Clinical Status | Notes |
|----------|-----------|-----------------|-------|
| Ambroxol | Pharmacological chaperone | Phase 2/3 | Restores GCase function |
| Venglustat | Substrate reduction | Phase 2 | Reduces glucosylceramide |
| AAV-GBA | Gene therapy | Phase 1/2 | Restores enzyme expression |
| Eliglustat | GCS inhibitor | Approved for GD | Brain-penetrant |

2. LRRK2-Associated Parkinson's Disease

Genetic Basis

[LRRK2](/genes/lrrk2) is the most common monogenic cause of PD, accounting for approximately 5-10% of familial PD and 1-3% of sporadic PD[@cookson2023].

| Variant | Domain | Effect | Population Prevalence |
|---------|--------|--------|----------------------|
| G2019S | Kinase | ↑ Kinase activity 2-3x | ~5% familial, ~1% sporadic PD |
| R1441C/G/H | ROC | ↓ GTPase activity | Basque, worldwide |
| N1437D | ROC | ↓ GTPase activity | Norwegian |
| Y1699C | COR | Intermediate | Worldwide |
| I2020T | Kinase | ↑ Kinase activity | Japanese families |

Genotype-Phenotype Correlations

LRRK2 genotype correlates with specific clinical features:

| Mutation | Age of Onset | Motor Phenotype | Cognitive Features |Penetrance by Age 80 |
|---------|--------------|-----------------|-------------------|---------------------|
| G2019S | 55-65 years | Typical PD | May develop later | 70-80% |
| R1441C/G | 50-60 years | More variable | Earlier dementia | 60-70% |
| Y1699C | 55-65 years | Typical | Variable | 50-60% |
| I2020T | 55-65 years | Typical | Variable | 50-70% |

Carrier Frequency and Geographic Distribution

LRRK2 variant frequency shows marked geographic and ethnic variation:

| Population | G2019S Frequency | Other Common Variants |
|------------|-----------------|----------------------|
| North African | 10-15% (familial) | — |
| European | 5% (familial), 1% (sporadic) | R1441C/G (Basque) |
| East Asian | 0.5-1% | G2385R, R1628P |
| South Asian | 2-3% | — |
| Ashkenazi Jewish | 5-10% | — |

Penetrance considerations: LRRK2 penetrance is incomplete and age-dependent. G2019S carriers have approximately 70-80% lifetime risk of developing PD, with risk increasing sharply after age 50.

Molecular Mechanisms

LRRK2 participates in multiple cellular pathways relevant to PD pathogenesis:

Kinase Inhibitors in Development

Multiple LRRK2 inhibitors have advanced through clinical development:

| Drug | Company | Mechanism | Stage | Key Challenges |
|------|---------|-----------|-------|-----------------|
| DNL151/DNL312 | Denali/Biogen | ATP-competitive | Phase 2/3 | BBB penetration |
| BIIB122 | Biogen | ATP-competitive | Phase 2b | Peripheral toxicity |
| PF-06649751 | Pfizer | ATP-competitive | Phase 1 | Long-term safety |

Gene Therapy Approaches

Novel therapeutic modalities include:

• Antisense oligonucleotides (ASOs): Reduce LRRK2 expression through RNase H-mediated cleavage
• RNAi approaches: Viral-delivered shRNA targeting mutant alleles
• CRISPR-based editing: Mutation-specific correction strategies using base editing

3. Gene-Environment Interactions

MDS 2026 featured significant new research on how genetic susceptibility factors interact with environmental exposures to modify PD risk. This represents a critical frontier in understanding disease etiology and developing prevention strategies.

Conceptual Framework

Gene-environment interactions (GxE) in PD follow several patterns:

LRRK2 and Environmental Exposures

Pesticide Exposure

The strongest gene-environment interaction evidence involves LRRK2 and pesticide exposure:

• Synergistic Risk: LRRK2 G2019S carriers exposed to pesticides have 2-3x higher PD risk than expected from additive effects
• Biological Mechanism: Both pesticide exposure and LRRK2 mutations impair autophagy-lysosome pathway
• Dose-Response: Risk increases with duration and intensity of pesticide exposure

Industrial Solvents

LRRK2 variants modify risk associated with:

• Trichloroethylene (TCE): Organic solvent exposure shows stronger association in LRRK2 carriers
• Perchloroethylene (PCE): Dry cleaning chemical exposure
• Mechanism: Both LRRK2 dysfunction and solvent exposure impair mitochondrial function

GBA and Environmental Interactions

Smoking

The relationship between smoking and PD is modified by GBA status:

• Inverse association: In non-carriers, smoking shows traditional inverse relationship with PD
• Attenuated effect: In GBA carriers, the protective effect of smoking is reduced
• Mechanism: GBA dysfunction may override nicotine's neuroprotective effects

Air Pollution

GBA variants modify air pollution-related PD risk:

• PM2.5 exposure: GBA carriers show stronger association with particulate matter exposure
• Mechanism: Both air pollution and GBA dysfunction impair lysosomal function
• Synergistic effect: Combined exposure produces greater risk than predicted

Gene-Environment Interaction Mechanisms

Research Findings from MDS 2026

Methodological Considerations

Challenges in studying gene-environment interactions:

• Exposure Assessment: Accurate quantification of historical exposures
• Sample Size: Large cohorts needed to detect interaction effects
• Population Stratification: Genetic background influences results
• Temporal Relationships: Latency between exposure and disease manifestation

4. Therapeutic Implications

Precision Medicine Approaches

| Genetic Subtype | Environmental Factor | Therapeutic Strategy | Development Stage |
|-----------------|---------------------|---------------------|-------------------|
| LRRK2 G2019S | Pesticide exposure | Kinase inhibitors | Phase 2/3 |
| GBA1 | Air pollution | Enzyme enhancement | Phase 2 |
| LRRK2 + GBA1 | Multiple | Combination therapy | Preclinical |
| Any | Solvents | Neuroprotective agents | Preclinical |

Combined LRRK2 + GBA Carriers

A subset of PD patients carry variants in both LRRK2 and GBA, representing a unique genetic subset with modified risk and therapeutic implications:

| Variant Combination | Clinical Feature | Therapeutic Approach |
|---------------------|-----------------|---------------------|
| LRRK2 + GBA1 | Earliest onset (~50 years), fastest progression | Combination therapy |
| LRRK2 + GBA1 | Highest cumulative risk | Kinase inhibitor + chaperone |
| LRRK2 only | Typical LRRK2-PD phenotype | LRRK2 inhibitors |
| GBA only | Typical GBA-PD phenotype | Enzyme enhancement |

Clinical trial considerations: Combined carriers may benefit from combination approaches targeting both LRRK2 kinase hyperactivity and GCase deficiency. Enrollment in genotype-stratified trials should consider this patient subset.

Prevention Strategies

For individuals with genetic susceptibility:

Clinical Recommendations

Based on gene-environment interaction research:

• Genetic Testing: Consider for individuals with significant environmental exposure history
• Counseling: Provide exposure avoidance guidance for carriers
• Clinical Trials: Enrich trials with genetically and environmentally defined populations

5. Emerging Research Directions

MDS 2026 highlighted several emerging areas:

6. Related Pages

• [GBA Gene](/genes/gba)
• [LRRK2 Gene](/genes/lrrk2)
• [MDS 2026 — PD Genetic and Molecular Mechanisms](/mechanisms/mds-2026-pd-genetic-molecular-mechanisms)
• [Environmental Toxins and PD Risk](/mechanisms/environmental-toxins-parkinson-risk)
• [Environmental Risk Factors for Neurodegeneration](/mechanisms/environmental-risk-factors)
• [Parkinson's Disease](/diseases/parkinsons-disease)

7. References